Literature DB >> 18709470

Mesothelioma epidemiology, carcinogenesis, and pathogenesis.

Haining Yang1, Joseph R Testa, Michele Carbone.   

Abstract

OPINION STATEMENT: The incidence of mesothelioma has gone from almost none to the current 2500-3000 cases per year in the USA. This estimate is an extrapolation based on information available from the Surveillance, Epidemiology and End Results (SEER) Program that collects information on approximately 12% of the US population. Mesothelioma is a cancer that is linked to exposure to carcinogenic mineral fibers. Asbestos and erionite have a proven causative role; the possible role of other mineral fibers in causing mesothelioma is being investigated. Asbestos is considered the main cause of mesothelioma in the US and in the Western world. The capacity of asbestos to induce mesothelioma has been linked to its ability to cause the release of TNF-alpha (that promotes mesothelial cells survival), other cytokines and growth factors, and of mutagenic oxygen radicals from exposed mesothelial cells and nearby macrophages. Some investigators proposed that as a consequence of the regulations to prevent exposure and to forbid and/or limit the use of asbestos, the incidence of mesothelioma in the US (and in some European countries) should have started to decline before or around the year 2000, and sharply decline thereafter. Unfortunately, there are no data available yet to support this optimistic hypothesis. Simian virus 40 (SV40) infection and radiation exposure are additional causes, although their contribution to the overall incidence of mesothelioma is unknown. Recent data from several laboratories indicate that asbestos exposure and SV40 infection are co-carcinogens in causing mesothelioma in rodents and in causing malignant transformation of human mesothelial cells in tissue culture. An exciting new development comes from the discovery that genetic susceptibility to mineral fiber carcinogenesis plays a critical role in the incidence of this cancer in certain families. It is hoped that the identification of this putative mesothelioma gene will lead to novel mechanistically driven preventive and therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18709470      PMCID: PMC2717086          DOI: 10.1007/s11864-008-0067-z

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  56 in total

1.  Diffuse malignant mesothelioma of the peritoneum following abdominal radiotherapy.

Authors:  A M Amin; C Mason; P Rowe
Journal:  Eur J Surg Oncol       Date:  2001-03       Impact factor: 4.424

Review 2.  Advances in malignant mesothelioma.

Authors:  Bruce W S Robinson; Richard A Lake
Journal:  N Engl J Med       Date:  2005-10-13       Impact factor: 91.245

3.  TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis.

Authors:  Haining Yang; Maurizio Bocchetta; Barbara Kroczynska; Amira G Elmishad; Yuanbin Chen; Zemin Liu; Concetta Bubici; Brooke T Mossman; Harvey I Pass; Joseph R Testa; Guido Franzoso; Michele Carbone
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-23       Impact factor: 11.205

Review 4.  Chrysotile as a cause of mesothelioma: an assessment based on epidemiology.

Authors:  Charles M Yarborough
Journal:  Crit Rev Toxicol       Date:  2006-02       Impact factor: 5.635

5.  Second cancers among 40,576 testicular cancer patients: focus on long-term survivors.

Authors:  Lois B Travis; Sophie D Fosså; Sara J Schonfeld; Mary L McMaster; Charles F Lynch; Hans Storm; Per Hall; Eric Holowaty; Aage Andersen; Eero Pukkala; Michael Andersson; Magnus Kaijser; Mary Gospodarowicz; Timo Joensuu; Randi J Cohen; John D Boice; Graça M Dores; Ethel S Gilbert
Journal:  J Natl Cancer Inst       Date:  2005-09-21       Impact factor: 13.506

6.  Some oral poliovirus vaccines were contaminated with infectious SV40 after 1961.

Authors:  Rochelle Cutrone; John Lednicky; Glynis Dunn; Paola Rizzo; Maurizio Bocchetta; Konstantin Chumakov; Philip Minor; Michele Carbone
Journal:  Cancer Res       Date:  2005-11-15       Impact factor: 12.701

Review 7.  Malignant mesothelioma.

Authors:  Bruce W S Robinson; Arthur W Musk; Richard A Lake
Journal:  Lancet       Date:  2005 Jul 30-Aug 5       Impact factor: 79.321

8.  A mouse model recapitulating molecular features of human mesothelioma.

Authors:  Deborah A Altomare; Charles A Vaslet; Kristine L Skele; Assunta De Rienzo; Karthik Devarajan; Suresh C Jhanwar; Andrea I McClatchey; Agnes B Kane; Joseph R Testa
Journal:  Cancer Res       Date:  2005-09-15       Impact factor: 12.701

9.  Comparison of Calidria chrysotile asbestos to pure tremolite: final results of the inhalation biopersistence and histopathology examination following short-term exposure.

Authors:  David M Bernstein; Jörg Chevalier; Paul Smith
Journal:  Inhal Toxicol       Date:  2005-08       Impact factor: 2.724

10.  The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression.

Authors:  Guang-Hui Xiao; Ryan Gallagher; Justin Shetler; Kristine Skele; Deborah A Altomare; Richard G Pestell; Suresh Jhanwar; Joseph R Testa
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

View more
  97 in total

1.  Telomerase activity in pleural malignant mesotheliomas.

Authors:  Amy Y M Au; Torben Hackl; Thomas R Yeager; Scott B Cohen; Harvey I Pass; Curtis C Harris; Roger R Reddel
Journal:  Lung Cancer       Date:  2011-01-31       Impact factor: 5.705

Review 2.  Review of malignant pleural mesothelioma survival after talc pleurodesis or surgery.

Authors:  Emanuela Taioli; Maaike van Gerwen; Meredith Mihalopoulos; Gil Moskowitz; Bian Liu; Raja Flores
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

3.  A rare cause of heart failure with preserved ejection fraction: primary pericardial mesothelioma masquerading as pericardial constriction.

Authors:  Russell Fernandes; Shravan Nosib; Dorothy Thomson; Nick Baniak
Journal:  BMJ Case Rep       Date:  2014-03-20

4.  Malignant peritoneal mesothelioma presenting with persistent high fever.

Authors:  Li-ying Chen; Ling-xiu Huang; Jin Wang; Yi Qian; Li-zheng Fang
Journal:  J Zhejiang Univ Sci B       Date:  2011-05       Impact factor: 3.066

5.  Computerized segmentation and measurement of malignant pleural mesothelioma.

Authors:  William F Sensakovic; Samuel G Armato; Christopher Straus; Rachael Y Roberts; Philip Caligiuri; Adam Starkey; Hedy L Kindler
Journal:  Med Phys       Date:  2011-01       Impact factor: 4.071

6.  Prognostic factors of survival in patients with malignant pleural mesothelioma: an analysis of the National Cancer Database.

Authors:  Maaike Van Gerwen; Naomi Alpert; Andrea Wolf; Nisha Ohri; Erik Lewis; Kenneth E Rosenzweig; Raja Flores; Emanuela Taioli
Journal:  Carcinogenesis       Date:  2019-06-10       Impact factor: 4.944

7.  Orthotopic pleural mesothelioma in mice: SPECT/CT and MR imaging with HER1- and HER2-targeted radiolabeled antibodies.

Authors:  Tapan K Nayak; Marcelino Bernardo; Diane E Milenic; Peter L Choyke; Martin W Brechbiel
Journal:  Radiology       Date:  2013-01-17       Impact factor: 11.105

8.  Receptor role of the annexin A2 in the mesothelial endocytosis of crocidolite fibers.

Authors:  Kyoko Yamashita; Hirotaka Nagai; Shinya Toyokuni
Journal:  Lab Invest       Date:  2015-04-27       Impact factor: 5.662

9.  Diagnostic value of mesothelin in pleural fluids: comparison with CYFRA 21-1 and CEA.

Authors:  Rosa Filiberti; Stefano Parodi; Roberta Libener; Giovanni Paolo Ivaldi; Pier Aldo Canessa; Donatella Ugolini; Barbara Bobbio; Paola Marroni
Journal:  Med Oncol       Date:  2013-03-27       Impact factor: 3.064

Review 10.  Asbestos, carbon nanotubes and the pleural mesothelium: a review of the hypothesis regarding the role of long fibre retention in the parietal pleura, inflammation and mesothelioma.

Authors:  Ken Donaldson; Fiona A Murphy; Rodger Duffin; Craig A Poland
Journal:  Part Fibre Toxicol       Date:  2010-03-22       Impact factor: 9.400

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.